DURECT Corporation Invites You to Join its Third Quarter 2001 Conference Call on the Web

Download PDF:

CUPERTINO, Calif., Oct 15, 2001 /PRNewswire via COMTEX/ — In conjunction with
DURECT Corporation’s (Nasdaq: DRRX) third quarter financial results press
release, you are invited to listen to its conference call that will be broadcast
live over the Internet on Wednesday, October 31, 2001 at 4:30 p.m. EDT with Jim
Brown, President and Chief Executive Officer, Tom Schreck, Chief Financial
Officer, and Schond Greenway, Senior Director, Investor Relations and Strategic

    What:     DURECT Corporation's third quarter earnings conference call

    When:     Wednesday, October 31, 2001, 4:30 p.m. EDT

    Where:    http://www.www.durect.com/wt/frame.php?page_name=investor

    How:      Live over the Internet -- Simply log on to the Web at the
              address listed above or access through DURECT's Website.

    Contact:  Suzanne Watson, DURECT Corporation, 408-864-7489,

If you are unable to participate during the live webcast, the call will be
archived at: http://www.www.durect.com/wt/frame.php?page_name=investor .

DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems for the treatment of chronic debilitating diseases and
enabling biotechnology-based pharmaceutical products. DURECT’s goal is to
deliver the right drug to the right site in the right amount at the right time.
DURECT’s pharmaceutical systems combine technology innovations from the medical
device and drug delivery industries with proprietary pharmaceutical and
biotechnology drug formulations. These capabilities can enable new drug
therapies or optimize existing therapies based on a broad range of compounds,
including small molecule pharmaceuticals as well as biotechnology molecules such
as proteins, peptides and genes. DURECT focuses on the treatment of chronic
diseases including pain, CNS disorders, cardiovascular disease and cancer. In
addition to holding an exclusive license from ALZA Corporation (NYSE: AZA) to
develop and commercialize products in selected fields based on the DUROS(R)
implant technology, DURECT also owns multiple proprietary drug delivery
platforms including SABER(TM), a patented and versatile depot technology and the
IntraEAR(R) catheters which have been used by physicians to treat inner ear

Founded in 1998, DURECT is headquartered in Cupertino, CA. The company’s World
Wide Web site can be accessed at http://www.www.durect.com . To join DURECT’s email
alert service, please register by selecting “Email Alerts” on the main Investor
Relations web page at http://www.www.durect.com . SABER(TM) and IntraEAR(R) are
trademarks of DURECT Corporation. DUROS(R) is a trademark of ALZA Corporation.

The statements in this press release regarding DURECT’s products in development,
product development plans, expected product benefits or potential product
markets are forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties include, but are
not limited to, DURECT’s ability to successfully complete clinical trials,
develop, manufacture and commercialize its products, obtain product and
manufacturing approvals from regulatory agencies, validate and qualify a
manufacturing facility and manage its growth and expenses, as well as
marketplace acceptance of DURECT’s products. Further information regarding these
and other risks is included in DURECT’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2001 filed with the SEC on August 14, 2001, and Annual
Report on Form 10-K for the fiscal year ended December 31, 2000 filed with the
SEC on March 30, 2001, under the heading “Factors that may effect future


CONTACT:          Schond L. Greenway, Senior Director, Investor Relations and
                  Strategic Planning of DURECT Corporation, +1-408-777-1417, or

URL:              http://www.www.durect.com
Copyright (C) 2001 PR Newswire.  All rights reserved.
Scroll to Top